Mikucki, Maryann E.Skitzki, Joseph J.Frelinger, John G.Odunsi, KunleGajewski, Thomas F.Luster, AndrewEvans, Sharon S.2016-07-142016Mikucki, Maryann E., Joseph J. Skitzki, John G. Frelinger, Kunle Odunsi, Thomas F. Gajewski, Andrew D. Luster, and Sharon S. Evans. 2016. “Unlocking tumor vascular barriers with CXCR3: Implications for cancer immunotherapy.” Oncoimmunology 5 (5): e1116675. doi:10.1080/2162402X.2015.1116675. http://dx.doi.org/10.1080/2162402X.2015.1116675.2162-4011http://nrs.harvard.edu/urn-3:HUL.InstRepos:27662187ABSTRACT Promising cancer immunotherapeutics depend on mobilization of cytotoxic T cells across tumor vascular barriers through mechanisms that are poorly understood. Recently, we discovered that the CXCR3 chemokine receptor uniquely functions as the master-regulator of cytotoxic CD8+ T cell extravasation and tumor control despite the multiplicity of chemokines available in the tumor landscape.en-USAdoptive T cell transfercancer immunotherapychemokine receptorCXCR3T cell traffickingtumor vesselsJournal Article2016-07-1410.1080/2162402X.2015.1116675